{"DataElement":{"publicId":"7414243","version":"1","preferredName":"Pegaspargase Dose Control Reason","preferredDefinition":"An indicator of the reason Pegaspargase dose was capped.","longName":"PEG_DOSE_CTRL_RSN","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"7414240","version":"1","preferredName":"Pegaspargase Dose Control","preferredDefinition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)_A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time._The act of directing or determining; regulation or maintenance of a function or action; a relation of constraint of one entity (thing or person or group) by another.","longName":"7391860v1.0:7414238v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"7391860","version":"1","preferredName":"Pegaspargase","preferredDefinition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)","longName":"C1200","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pegaspargase","conceptCode":"C1200","definition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACC9791F-8A7D-4343-E053-4EBD850AD386","latestVersionIndicator":"Yes","beginDate":"2020-08-13","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-08-13","modifiedBy":"ONEDATA","dateModified":"2020-08-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7414238","version":"1","preferredName":"Dose Control","preferredDefinition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.:The act of directing or determining; regulation or maintenance of a function or action; a relation of constraint of one entity (thing or person or group) by another.","longName":"C25488:C61299","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Control","conceptCode":"C61299","definition":"The act of directing or determining; regulation or maintenance of a function or action; a relation of constraint of one entity (thing or person or group) by another.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AEE4DB12-0144-41B5-E053-4EBD850A47F8","latestVersionIndicator":"Yes","beginDate":"2020-09-09","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-09","modifiedBy":"ONEDATA","dateModified":"2020-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AEE4DB12-0155-41B5-E053-4EBD850A47F8","latestVersionIndicator":"Yes","beginDate":"2020-09-09","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-09","modifiedBy":"SETRAKIN","dateModified":"2020-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7414241","version":"1","preferredName":"Dose Control Reason","preferredDefinition":"An explanation of the cause of some phenomenon or action.","longName":"7414241v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"20","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"3126125","version":"1","preferredName":"Other","longName":"3126125","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8D01180C-814A-B8B4-E040-BB89AD432507","latestVersionIndicator":"Yes","beginDate":"2010-08-04","endDate":null,"createdBy":"MAESKEB","dateCreated":"2010-08-04","modifiedBy":"KUMMEROA","dateModified":"2023-03-07","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/03/2015.","administrativeNotes":"2023.3.7 Alt VM added per ticket request CADSR0002119. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AEE47B7C-24A8-41BF-E053-4EBD850AA00F","beginDate":"2020-09-09","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-09","modifiedBy":"ONEDATA","dateModified":"2020-09-09","deletedIndicator":"No"},{"value":"Hepatic dysfunction","valueDescription":"Dysfunction Hepatic","ValueMeaning":{"publicId":"7414242","version":"1","preferredName":"Dysfunction Hepatic","longName":"7414242","preferredDefinition":"Disturbance, impairment or abnormality of function.: Pertaining to, affecting, or associated with the liver.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dysfunction","conceptCode":"C53526","definition":"Disturbance, impairment or abnormality of function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Hepatic","conceptCode":"C13308","definition":"Pertaining to, affecting, or associated with the liver.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AEE47B7C-24B5-41BF-E053-4EBD850AA00F","latestVersionIndicator":"Yes","beginDate":"2020-09-09","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-09","modifiedBy":"ONEDATA","dateModified":"2020-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AEE47B7C-24CE-41BF-E053-4EBD850AA00F","beginDate":"2020-09-09","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-09","modifiedBy":"ONEDATA","dateModified":"2020-09-09","deletedIndicator":"No"},{"value":"Age","valueDescription":"Age","ValueMeaning":{"publicId":"2815178","version":"1","preferredName":"Age","longName":"2815178","preferredDefinition":"A period or stage in life, usually stated in years since birth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Age","conceptCode":"C25150","definition":"How long something has existed; elapsed time since birth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5DCAAC7C-6786-4858-E040-BB89A6432A2D","latestVersionIndicator":"Yes","beginDate":"2008-12-11","endDate":null,"createdBy":"LEEB","dateCreated":"2008-12-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AEE47B7C-24D8-41BF-E053-4EBD850AA00F","beginDate":"2020-09-09","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-09","modifiedBy":"ONEDATA","dateModified":"2020-09-09","deletedIndicator":"No"},{"value":"Obesity","valueDescription":"Obesity","ValueMeaning":{"publicId":"2945865","version":"1","preferredName":"Obesity","longName":"2945865","preferredDefinition":"Having a high amount of body fat (body mass index [BMI] of 30 or more).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Obesity","conceptCode":"C3283","definition":"Having a high amount of body fat (body mass index [BMI] of 30 or more).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74597246-17B3-6D19-E040-BB89AD431E08","latestVersionIndicator":"Yes","beginDate":"2009-09-24","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AEE47B7C-24E2-41BF-E053-4EBD850AA00F","beginDate":"2020-09-09","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-09","modifiedBy":"ONEDATA","dateModified":"2020-09-09","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2240632","version":"1","preferredName":"Reason","preferredDefinition":"An explanation of the cause of some phenomenon or action.","longName":"C25638","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Reason","conceptCode":"C25638","definition":"An explanation of the cause of some phenomenon or action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F9FA7953-8391-043D-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-30","endDate":null,"createdBy":"PWEST","dateCreated":"2005-06-30","modifiedBy":"ONEDATA","dateModified":"2005-06-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AEE47B7C-2491-41BF-E053-4EBD850AA00F","latestVersionIndicator":"Yes","beginDate":"2020-09-09","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-09","modifiedBy":"SETRAKIN","dateModified":"2020-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"If capped, reason dose was ca","type":"Preferred Question Text","description":"If capped, reason dose was capped:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AEE4EA33-2A26-4335-E053-4EBD850A2B9F","latestVersionIndicator":"Yes","beginDate":"2020-09-09","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-09","modifiedBy":"SETRAKIN","dateModified":"2020-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}